Edge Therapeutics Announces Pricing of Its Initial Public Offering

BERKELEY HEIGHTS, N.J., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced the pricing of its initial public offering of 7,315,151 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions.  All of the shares of common stock are being offered by Edge Therapeutics. In addition, Edge Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,097,272 shares of common stock at the same price, to cover over-allotments, if any. The shares are scheduled to begin trading on The NASDAQ Global Select Market on October 1, 2015 under the ticker symbol "EDGE."  

Leerink Partners and Credit Suisse are acting as joint book-running managers for the offering.  Guggenheim Securities and JMP Securities are acting as co-managers. 

The offering is being made only by means of a prospectus.  A copy of the final prospectus related to this offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected], or by phone at (800) 808-7525, ext. 6124, or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by email at [email protected].

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on September 30, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Edge Therapeutics

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain. For additional information about Edge Therapeutics, please visit www.edgetherapeutics.com.

Investor Contact:
Allison Wey
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)
Email: [email protected]

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera